Pulmonary Endarterectomy: Risk Factors for Early and Late Mortality
- PMID: 39231495
- PMCID: PMC11961224
- DOI: 10.1055/a-2409-5944
Pulmonary Endarterectomy: Risk Factors for Early and Late Mortality
Abstract
Background: Pulmonary endarterectomy (PEA) is a potentially curative treatment option for chronic thromboembolic pulmonary hypertension (CTEPH). This study aimed to identify predictors of short- and long-term outcomes after PEA for CTEPH patients, including age.
Methods: Patients who underwent surgery between March 2014 and January 2024 were included in the study. Perioperative and follow-up data were retrospectively studied, including age, in-hospital mortality, 1- and 5-year survival, and the length of intensive care unit (ICU) and hospital stays after PEA.
Results: In total, 834 consecutive patients (mean age 51 ± 15.3 years) underwent PEA and were included in the analysis. The in-hospital mortality rate was 7.8% (n = 65), while overall mortality rates at 1 and 5 years were 10.6% and 11.3%, respectively. The in-hospital mortality rate was 6.7% for patients <70 years compared with 12.4% for patients ≥70 years (p = 0.029). In the multivariate analysis of mortality, age (p = 0.007), and length of ICU stay (p = 0.028) emerged as independent predictors of in-hospital mortality, while the Charlson Comorbidity Index (p < 0.001) and 6-minute walk distance (p = 0.005) were also significant predictors of 1-year survival.
Conclusion: Despite higher short-term mortality rates, PEA was feasible and well-tolerated among elderly patients. Despite surgical advancements, careful patient selection remains crucial, particularly in the presence of comorbidities. Significant clinical and hemodynamic improvements were observed, along with favorable long-term survival outcomes.
The Author(s). This is an open access article published by Thieme under the terms of the Creative Commons Attribution-NonDerivative-NonCommercial License, permitting copying and reproduction so long as the original work is given appropriate credit. Contents may not be used for commercial purposes, or adapted, remixed, transformed or built upon. (https://creativecommons.org/licenses/by-nc-nd/4.0/).
Conflict of interest statement
None declared.
Figures
References
-
- ESC Scientific Document Group . Galiè N, Humbert M, Vachiery J L et al.2015 ESC/ERS Guidelines for the diagnosis and treatment of pulmonary hypertension: The Joint Task Force for the Diagnosis and Treatment of Pulmonary Hypertension of the European Society of Cardiology (ESC) and the European Respiratory Society (ERS): Endorsed by: Association for European Paediatric and Congenital Cardiology (AEPC), International Society for Heart and Lung Transplantation (ISHLT) Eur Heart J. 2016;37(01):67–119. - PubMed
-
- ESC/ERS Scientific Document Group . Humbert M, Kovacs G, Hoeper M M et al.2022 ESC/ERS Guidelines for the diagnosis and treatment of pulmonary hypertension. Eur Heart J. 2022;43(38):3618–3731. - PubMed
-
- Pepke-Zaba J, Delcroix M, Lang I et al.Chronic thromboembolic pulmonary hypertension (CTEPH): results from an international prospective registry. Circulation. 2011;124(18):1973–1981. - PubMed
MeSH terms
LinkOut - more resources
Full Text Sources
Medical